Amneal Pharmaceuticals Operating Expenses Growth & History (AMRX)
Amneal Pharmaceuticals's operating expenses was $719.2M for fiscal 2025.
View full Amneal Pharmaceuticals company overviewAmneal Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $719.2M | −$51.9M | −6.73% |
| 2024 | 2024-12-31 | $771.1M | $154.9M | +25.14% |
| 2023 | 2023-12-31 | $616.2M | −$263.4M | −29.95% |
| 2022 | 2022-12-31 | $879.6M | $263.4M | +42.74% |
| 2021 | 2021-12-31 | $616.3M | $79.0M | +14.71% |
| 2020 | 2020-12-31 | $537.2M | −$64.4M | −10.71% |
| 2019 | 2019-12-31 | $601.7M | −$134.4M | −18.26% |
| 2018 | 2018-12-31 | $736.1M | $455.0M | +161.88% |
| 2017 | 2017-12-31 | $281.1M | −$31.5M | −10.08% |
| 2016 | 2016-12-31 | $312.6M | — | — |
Amneal Pharmaceuticals quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $204.7M | $29.9M | +17.07% |
| Q1 2026 | 2026-03-31 | $178.3M | $22.8M | +14.66% |
| Q4 2025 | 2025-12-31 | $185.2M | −$1.9M | −1.03% |
| Q3 2025 | 2025-09-30 | $203.6M | $22.9M | +12.66% |
| Q2 2025 | 2025-06-30 | $174.9M | $20.4M | +13.21% |
| Q1 2025 | 2025-03-31 | $155.5M | −$93.3M | −37.48% |
| Q4 2024 | 2024-12-31 | $187.1M | $11.4M | +6.52% |
| Q3 2024 | 2024-09-30 | $180.7M | $23.9M | +15.21% |
| Q2 2024 | 2024-06-30 | $154.5M | $14.5M | +10.39% |
| Q1 2024 | 2024-03-31 | $248.8M | $105.1M | +73.10% |
| Q4 2023 | 2023-12-31 | $175.6M | −$3.7M | −2.08% |
| Q3 2023 | 2023-09-30 | $156.9M | $7.0M | +4.67% |
| Q2 2023 | 2023-06-30 | $139.9M | −$259.2M | −64.94% |
| Q1 2023 | 2023-03-31 | $143.7M | −$7.5M | −4.98% |
| Q4 2022 | 2022-12-31 | $179.4M | $24.1M | +15.54% |
| Q3 2022 | 2022-09-30 | $149.9M | −$20.1M | −11.83% |
| Q2 2022 | 2022-06-30 | $399.1M | $253.8M | +174.55% |
| Q1 2022 | 2022-03-31 | $151.3M | $5.6M | +3.85% |
| Q4 2021 | 2021-12-31 | $155.2M | $8.3M | +5.67% |
| Q3 2021 | 2021-09-30 | $170.0M | $38.8M | +29.62% |
| Q2 2021 | 2021-06-30 | $145.4M | $11.9M | +8.91% |
| Q1 2021 | 2021-03-31 | $145.7M | $19.9M | +15.87% |
| Q4 2020 | 2020-12-31 | $146.9M | $13.5M | +10.14% |
| Q3 2020 | 2020-09-30 | $131.2M | −$35.6M | −21.33% |
| Q2 2020 | 2020-06-30 | $133.5M | $9.3M | +7.51% |
| Q1 2020 | 2020-03-31 | $125.7M | −$51.7M | −29.15% |
| Q4 2019 | 2019-12-31 | $133.4M | — | — |
| Q3 2019 | 2019-09-30 | $166.7M | $41.2M | +32.78% |
| Q2 2019 | 2019-06-30 | $124.2M | −$235.2M | −65.45% |
| Q1 2019 | 2019-03-31 | $177.4M | $177.4M | — |
| Q3 2018 | 2018-09-30 | $125.5M | $69.3M | +123.16% |
| Q2 2018 | 2018-06-30 | $359.4M | $280.2M | +354.13% |
| Q1 2018 · Mar 31 | 2018-03-31 | $0 | — | — |
| Q4 2017 | 2017-12-31 | $0 | — | — |
| Q3 2017 | 2017-09-30 | $56.3M | — | — |
| Q2 2017 | 2017-06-30 | $79.1M | — | — |
Amneal Pharmaceuticals operating expenses trends
Over the last five fiscal years, Amneal Pharmaceuticals's operating expenses increased from $537.2M to $719.2M, a change of $182.0M. The latest reported quarter, Q2 2026, shows $204.7M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amneal Pharmaceuticals source filings ↗